rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
3
|
pubmed:dateCreated |
1999-4-16
|
pubmed:abstractText |
Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease. A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics. This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0085-2538
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
55
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
821-32
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:10027919-Animals,
pubmed-meshheading:10027919-Bone Diseases, Metabolic,
pubmed-meshheading:10027919-Bone Remodeling,
pubmed-meshheading:10027919-Calcitriol,
pubmed-meshheading:10027919-Calcium,
pubmed-meshheading:10027919-Disease Models, Animal,
pubmed-meshheading:10027919-Dogs,
pubmed-meshheading:10027919-Female,
pubmed-meshheading:10027919-Humans,
pubmed-meshheading:10027919-Hypercalcemia,
pubmed-meshheading:10027919-Hyperparathyroidism, Secondary,
pubmed-meshheading:10027919-Kidney Failure, Chronic,
pubmed-meshheading:10027919-Nephrectomy,
pubmed-meshheading:10027919-Parathyroid Hormone,
pubmed-meshheading:10027919-Phosphorus,
pubmed-meshheading:10027919-Time Factors
|
pubmed:year |
1999
|
pubmed:articleTitle |
22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
|
pubmed:affiliation |
Division of Nephrology, Bone and Mineral Metabolism, Department of Internal Medicine, University of Kentucky, Lexington 40536-0084, USA.
|
pubmed:publicationType |
Journal Article
|